Rational design of an influenza-COVID-19 chimeric protective vaccine with HA-stalk and S-RBD
Highly contagious respiratory illnesses like influenza and COVID-19 pose serious risks to public health. A two-in-one vaccine would be ideal to avoid multiple vaccinations for these diseases. Here, we generated a chimeric receptor binding domain of the spike protein (S-RBD) and hemagglutinin (HA)-st...
| Main Authors: | , , , , , , , , , , , , , , , , , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Taylor & Francis Group
2023-12-01
|
| Series: | Emerging Microbes and Infections |
| Subjects: | |
| Online Access: | https://www.tandfonline.com/doi/10.1080/22221751.2023.2231573 |
| _version_ | 1827211469497827328 |
|---|---|
| author | Yulei Li Peipei Liu Tianjiao Hao Sheng Liu Xi Wang Yufeng Xie Ke Xu Wenwen Lei Cheng Zhang Pu Han Ying Li Xiyue Jin Yu Huan Yafei Lu Rong Zhang Xiaoyan Li Xin Zhao Kun Xu Pu Liao Xuancheng Lu Yuhai Bi Hao Song Guizhen Wu Baoli Zhu George F. Gao |
| author_facet | Yulei Li Peipei Liu Tianjiao Hao Sheng Liu Xi Wang Yufeng Xie Ke Xu Wenwen Lei Cheng Zhang Pu Han Ying Li Xiyue Jin Yu Huan Yafei Lu Rong Zhang Xiaoyan Li Xin Zhao Kun Xu Pu Liao Xuancheng Lu Yuhai Bi Hao Song Guizhen Wu Baoli Zhu George F. Gao |
| author_sort | Yulei Li |
| collection | DOAJ |
| description | Highly contagious respiratory illnesses like influenza and COVID-19 pose serious risks to public health. A two-in-one vaccine would be ideal to avoid multiple vaccinations for these diseases. Here, we generated a chimeric receptor binding domain of the spike protein (S-RBD) and hemagglutinin (HA)-stalk-based vaccine for both SARS-CoV-2 and influenza viruses. The S-RBD from SARS-CoV-2 Delta was fused to the headless HA from H1N1 (H1Delta), creating a chimera that forms trimers in solution. The cryo-electron microscopy structure of the chimeric protein complexed with the RBD-targeting CB6 and the HA-stalk-targeting CR9114 antibodies shows that the trimeric protein is stable and accessible for neutralizing antibody binding. Immunization with the vaccine elicited high and long-lasting neutralizing antibodies and effectively protected mice against the challenges of lethal H1N1 or heterosubtypic H5N8, as well as the SARS-CoV-2 Delta or Omicron BA.2 variants. Overall, this study offers a two-in-one universal vaccine design to combat infections caused by both SARS-CoV-2 variants of concern and influenza viruses. |
| first_indexed | 2024-03-08T11:52:24Z |
| format | Article |
| id | doaj.art-78b599e9f4e1408ba9f1981250f3f088 |
| institution | Directory Open Access Journal |
| issn | 2222-1751 |
| language | English |
| last_indexed | 2025-03-21T13:44:09Z |
| publishDate | 2023-12-01 |
| publisher | Taylor & Francis Group |
| record_format | Article |
| series | Emerging Microbes and Infections |
| spelling | doaj.art-78b599e9f4e1408ba9f1981250f3f0882024-06-26T10:39:27ZengTaylor & Francis GroupEmerging Microbes and Infections2222-17512023-12-0112210.1080/22221751.2023.2231573Rational design of an influenza-COVID-19 chimeric protective vaccine with HA-stalk and S-RBDYulei Li0Peipei Liu1Tianjiao Hao2Sheng Liu3Xi Wang4Yufeng Xie5Ke Xu6Wenwen Lei7Cheng Zhang8Pu Han9Ying Li10Xiyue Jin11Yu Huan12Yafei Lu13Rong Zhang14Xiaoyan Li15Xin Zhao16Kun Xu17Pu Liao18Xuancheng Lu19Yuhai Bi20Hao Song21Guizhen Wu22Baoli Zhu23George F. Gao24Savaid Medical School, University of Chinese Academy of Sciences, Beijing, People’s Republic of ChinaNHC Key Laboratory of Biosafety, National Institute for Viral Disease Control and Prevention, Chinese Center for Disease Control and Prevention, Beijing, People’s Republic of ChinaCAS Key Laboratory of Pathogen Microbiology and Immunology, Institute of Microbiology, Chinese Academy of Sciences, Beijing, People’s Republic of ChinaCryo-EM Center, Southern University of Science and Technology, Shenzhen, People’s Republic of ChinaCAS Key Laboratory of Pathogen Microbiology and Immunology, Institute of Microbiology, Chinese Academy of Sciences, Beijing, People’s Republic of ChinaDepartment of Basic Medical Sciences, School of Medicine, Tsinghua University, Beijing, People’s Republic of ChinaNHC Key Laboratory of Biosafety, National Institute for Viral Disease Control and Prevention, Chinese Center for Disease Control and Prevention, Beijing, People’s Republic of ChinaNHC Key Laboratory of Biosafety, National Institute for Viral Disease Control and Prevention, Chinese Center for Disease Control and Prevention, Beijing, People’s Republic of ChinaXinjiang Key Laboratory of Biological Resources and Genetic Engineering, College of Life Science and Technology, Xinjiang University, Urumqi, People’s Republic of ChinaCAS Key Laboratory of Pathogen Microbiology and Immunology, Institute of Microbiology, Chinese Academy of Sciences, Beijing, People’s Republic of ChinaSavaid Medical School, University of Chinese Academy of Sciences, Beijing, People’s Republic of ChinaSchool of Life Sciences, Division of Life Sciences and Medicine, University of Science and Technology of China, Hefei, People’s Republic of ChinaCAS Key Laboratory of Pathogen Microbiology and Immunology, Institute of Microbiology, Chinese Academy of Sciences, Beijing, People’s Republic of ChinaCAS Key Laboratory of Pathogen Microbiology and Immunology, Institute of Microbiology, Chinese Academy of Sciences, Beijing, People’s Republic of ChinaState Key Laboratory for Conservation and Utilization of Subtropical Agro-Bioresources, Guangxi University, Nanning, People’s Republic of ChinaLaboratory Animal Center, Chinese Center for Disease Control and Prevention (China CDC), Beijing, People’s Republic of ChinaCAS Key Laboratory of Pathogen Microbiology and Immunology, Institute of Microbiology, Chinese Academy of Sciences, Beijing, People’s Republic of ChinaResearch Network of Immunity and Health (RNIH), Beijing Institutes of Life Science, Chinese Academy of Sciences, Beijing, People’s Republic of ChinaDepartment of Clinical Laboratory, Chongqing General Hospital, Chongqing, People’s Republic of ChinaLaboratory Animal Center, Chinese Center for Disease Control and Prevention (China CDC), Beijing, People’s Republic of ChinaCAS Key Laboratory of Pathogen Microbiology and Immunology, Institute of Microbiology, Chinese Academy of Sciences, Beijing, People’s Republic of ChinaUniversity of Chinese Academy of Sciences, Beijing, People’s Republic of ChinaNHC Key Laboratory of Biosafety, National Institute for Viral Disease Control and Prevention, Chinese Center for Disease Control and Prevention, Beijing, People’s Republic of ChinaCAS Key Laboratory of Pathogen Microbiology and Immunology, Institute of Microbiology, Chinese Academy of Sciences, Beijing, People’s Republic of ChinaSavaid Medical School, University of Chinese Academy of Sciences, Beijing, People’s Republic of ChinaHighly contagious respiratory illnesses like influenza and COVID-19 pose serious risks to public health. A two-in-one vaccine would be ideal to avoid multiple vaccinations for these diseases. Here, we generated a chimeric receptor binding domain of the spike protein (S-RBD) and hemagglutinin (HA)-stalk-based vaccine for both SARS-CoV-2 and influenza viruses. The S-RBD from SARS-CoV-2 Delta was fused to the headless HA from H1N1 (H1Delta), creating a chimera that forms trimers in solution. The cryo-electron microscopy structure of the chimeric protein complexed with the RBD-targeting CB6 and the HA-stalk-targeting CR9114 antibodies shows that the trimeric protein is stable and accessible for neutralizing antibody binding. Immunization with the vaccine elicited high and long-lasting neutralizing antibodies and effectively protected mice against the challenges of lethal H1N1 or heterosubtypic H5N8, as well as the SARS-CoV-2 Delta or Omicron BA.2 variants. Overall, this study offers a two-in-one universal vaccine design to combat infections caused by both SARS-CoV-2 variants of concern and influenza viruses.https://www.tandfonline.com/doi/10.1080/22221751.2023.2231573Universal vaccineSARS-CoV-2Omicroninfluenzasubunit vaccinechimeric antigen |
| spellingShingle | Yulei Li Peipei Liu Tianjiao Hao Sheng Liu Xi Wang Yufeng Xie Ke Xu Wenwen Lei Cheng Zhang Pu Han Ying Li Xiyue Jin Yu Huan Yafei Lu Rong Zhang Xiaoyan Li Xin Zhao Kun Xu Pu Liao Xuancheng Lu Yuhai Bi Hao Song Guizhen Wu Baoli Zhu George F. Gao Rational design of an influenza-COVID-19 chimeric protective vaccine with HA-stalk and S-RBD Emerging Microbes and Infections Universal vaccine SARS-CoV-2 Omicron influenza subunit vaccine chimeric antigen |
| title | Rational design of an influenza-COVID-19 chimeric protective vaccine with HA-stalk and S-RBD |
| title_full | Rational design of an influenza-COVID-19 chimeric protective vaccine with HA-stalk and S-RBD |
| title_fullStr | Rational design of an influenza-COVID-19 chimeric protective vaccine with HA-stalk and S-RBD |
| title_full_unstemmed | Rational design of an influenza-COVID-19 chimeric protective vaccine with HA-stalk and S-RBD |
| title_short | Rational design of an influenza-COVID-19 chimeric protective vaccine with HA-stalk and S-RBD |
| title_sort | rational design of an influenza covid 19 chimeric protective vaccine with ha stalk and s rbd |
| topic | Universal vaccine SARS-CoV-2 Omicron influenza subunit vaccine chimeric antigen |
| url | https://www.tandfonline.com/doi/10.1080/22221751.2023.2231573 |
| work_keys_str_mv | AT yuleili rationaldesignofaninfluenzacovid19chimericprotectivevaccinewithhastalkandsrbd AT peipeiliu rationaldesignofaninfluenzacovid19chimericprotectivevaccinewithhastalkandsrbd AT tianjiaohao rationaldesignofaninfluenzacovid19chimericprotectivevaccinewithhastalkandsrbd AT shengliu rationaldesignofaninfluenzacovid19chimericprotectivevaccinewithhastalkandsrbd AT xiwang rationaldesignofaninfluenzacovid19chimericprotectivevaccinewithhastalkandsrbd AT yufengxie rationaldesignofaninfluenzacovid19chimericprotectivevaccinewithhastalkandsrbd AT kexu rationaldesignofaninfluenzacovid19chimericprotectivevaccinewithhastalkandsrbd AT wenwenlei rationaldesignofaninfluenzacovid19chimericprotectivevaccinewithhastalkandsrbd AT chengzhang rationaldesignofaninfluenzacovid19chimericprotectivevaccinewithhastalkandsrbd AT puhan rationaldesignofaninfluenzacovid19chimericprotectivevaccinewithhastalkandsrbd AT yingli rationaldesignofaninfluenzacovid19chimericprotectivevaccinewithhastalkandsrbd AT xiyuejin rationaldesignofaninfluenzacovid19chimericprotectivevaccinewithhastalkandsrbd AT yuhuan rationaldesignofaninfluenzacovid19chimericprotectivevaccinewithhastalkandsrbd AT yafeilu rationaldesignofaninfluenzacovid19chimericprotectivevaccinewithhastalkandsrbd AT rongzhang rationaldesignofaninfluenzacovid19chimericprotectivevaccinewithhastalkandsrbd AT xiaoyanli rationaldesignofaninfluenzacovid19chimericprotectivevaccinewithhastalkandsrbd AT xinzhao rationaldesignofaninfluenzacovid19chimericprotectivevaccinewithhastalkandsrbd AT kunxu rationaldesignofaninfluenzacovid19chimericprotectivevaccinewithhastalkandsrbd AT puliao rationaldesignofaninfluenzacovid19chimericprotectivevaccinewithhastalkandsrbd AT xuanchenglu rationaldesignofaninfluenzacovid19chimericprotectivevaccinewithhastalkandsrbd AT yuhaibi rationaldesignofaninfluenzacovid19chimericprotectivevaccinewithhastalkandsrbd AT haosong rationaldesignofaninfluenzacovid19chimericprotectivevaccinewithhastalkandsrbd AT guizhenwu rationaldesignofaninfluenzacovid19chimericprotectivevaccinewithhastalkandsrbd AT baolizhu rationaldesignofaninfluenzacovid19chimericprotectivevaccinewithhastalkandsrbd AT georgefgao rationaldesignofaninfluenzacovid19chimericprotectivevaccinewithhastalkandsrbd |